Below is the list of 5 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. For a detailed analysis and Mark Lampert’s investment philosophy, you can directly jump to 10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund.
5. Merus N.V. (NASDAQ:MRUS)
Biotechnology Value Fund’s Stake Value: $153 million
Percentage of Biotechnology Value Fund’s 13F Portfolio: 5.75%
Number of Hedge Fund Holders: 23
Merus N.V. (NASDAQ:MRUS) is the long-running stock holding of Mark Lampert’s fund. The fund first initiated a position in the pharma stock in the first quarter of 2019. At the end of the June quarter, BVF held 7.3 million shares of Merus, representing 18.8% of the ownership in the company.
4. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Biotechnology Value Fund’s Stake Value: $168 million
Percentage of Biotechnology Value Fund’s 13F Portfolio: 6.31%
Number of Hedge Fund Holders: 27
The developer of peptide-based therapeutic drugs, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the top pharma stocks to buy because of a staggering share price gain since the beginning of this year. Its stock price is up almost 50% year to date.
3. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Biotechnology Value Fund’s Stake Value: $186million
Percentage of Biotechnology Value Fund’s 13F Portfolio: 6.99%
Number of Hedge Fund Holders: 17
San Francisco-based Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is the third-largest stock holding of Mark Lampert’s Biotechnology Value fund, according to the June quarter filings. The fund first initiated a position in Olema during the final quarter of last year and left its position unchanged in the second quarter of 2021.
2. argenx SE (NASDAQ:ARGX)
Biotechnology Value Fund’s Stake Value: $196million
Percentage of Biotechnology Value Fund’s 13F Portfolio: 7.35%
Number of Hedge Fund Holders: 27
Mark Lampert’s Biotechnology Value fund increased its existing position in argenx SE (NASDAQ:ARGX) by 110% during the second quarter to make it the second-largest stock holding of its 13F portfolio. Shares of argenx struggled in the past couple of months amid broader market trends. Besides short-term volatility, its stock price soared from its IPO price of $20 in June 2017 to around $281 at present.
At the end of the second quarter, argenx SE was in 27 hedge funds portfolios, flat compared to the previous quarter. Baker Bros. Advisors and VenBio Select Advisor were the leading stakeholders in the company while Biotechnology Value Fund was the fourth largest stakeholder.
1. GH Research PLC (NASDAQ:GHRS)
Biotechnology Value Fund’s Stake Value: $201 million
Percentage of Biotechnology Value Fund’s 13F Portfolio: 7.55%
Number of Hedge Fund Holders: 27
Biotechnology Value Fund initiated a new position in GH Research PLC (NASDAQ:GHRS) during the second quarter of 2021. Debuted on NASDAQ in June 2021, shares of GH Research experienced a lot of volatility in the past couple of months. Mark Lampert’s fund held 9.2 million shares of depression drug-focused company.
You can also take a look at Extreme Dividend Stocks With Upside Potential and 10 Pharmaceutical Stocks to Buy According to Lawrence Hawkins’ Prosight Capital.
